Expert Ratings for Travere Therapeutics
Portfolio Pulse from Benzinga Insights
Analysts have provided various ratings for Travere Therapeutics (NASDAQ:TVTX) within the last quarter, with a majority being bullish. The average price target for Travere Therapeutics over the next 12 months is $27.9, a 23.41% decrease from the previous average price target of $36.43.
July 18, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Travere Therapeutics has received mostly bullish ratings from analysts. However, the average 12-month price target has decreased by 23.41% to $27.9.
The majority of analysts have given Travere Therapeutics a bullish rating, indicating a positive outlook for the stock. However, the decrease in the average 12-month price target suggests that analysts expect the stock's price to decrease in the short term. This could potentially lead to a neutral impact on the stock's price.
CONFIDENCE 90
IMPORTANCE 75
RELEVANCE 100